Treatment of stage IIIA-N2 EGFR-mutant non-small cell lung adenocarcinoma.

Abstract

Lung cancer remains the leading cause of death worldwide and is the most common cancer both in incidence and mortality (1.35 million deaths annually). Lobectomy, along with hilar and mediastinal lymph node dissection, is the standard surgical treatment for lung cancer. Roughly 20–25% of patients diagnosed with non-small cell lung cancer (NSCLC) are suitable for surgical resection with curative intent (1).